Completed PHASE1 INTERVENTIONAL 1-arm NCT05244759

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

A Single Dose Study to Assess the Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 in Healthy Male Subjects After Oral Dosing

Sponsor: Bellus Health Inc. - a GSK company

Conditions Healthy

Interventions [14C]-BLU-5937

Updated 4 times since 2022 Last updated: Feb 11, 2022 Started: Aug 25, 2020 Primary completion: Sep 23, 2020 Completion: Mar 2, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Bellus Health Inc. - a GSK company leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1
Mar 2022 — Jan 2024 [monthly]

Completed PHASE1

First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bellus Health Inc. - a GSK company

Data source: Bellus Health Inc. - a GSK company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nottingham, United Kingdom